Press release
Emerging Sub-Segments Transforming the G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Landscape
G Protein‐Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market
Forecasted Market Growth and Expansion Potential of the GPRC5D Targeted Therapies Market
The market for GPRC5D-targeted therapies is anticipated to experience remarkable expansion in the coming years. Valued at $2.42 billion by 2030, this market is expected to grow at an impressive compound annual growth rate (CAGR) of 32.9%. This surge is driven by several factors, including an increase in regulatory approvals for targeted biologics and a rising demand for personalized cancer treatments. Additionally, advancements in next-generation immunotherapy platforms, greater investments in precision medicine ecosystems, and the widespread adoption of biomarker-based therapy selection are fueling this upward trajectory. Notable trends shaping this market include the development of bispecific antibody therapies, a stronger emphasis on GPRC5D biomarker-driven patient selection, the growing use of CAR-T cell platforms, expansion of precision oncology clinical pipelines, and advanced integration of companion diagnostics.
Download a free sample of the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33116&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR
Key Drivers Behind the Growth of the GPRC5D Targeted Therapies Market
One significant driver of this market's growth is the increasing regulatory support enabling faster approval pathways for targeted biologics, allowing innovative therapies to reach patients more quickly. This regulatory momentum helps accelerate the introduction of cutting-edge treatments aimed at specific biomarkers like GPRC5D.
Another crucial factor is the rising demand for personalized cancer treatments, which tailor therapies to an individual's unique genetic and molecular profile. This approach improves efficacy and reduces side effects, making it highly attractive to patients and healthcare providers alike.
Top Industry Players Advancing GPRC5D Targeted Therapies
The competitive landscape of the GPRC5D targeted therapies market includes several influential global companies such as Johnson and Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, and Genentech Inc. Other key contributors include Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., and Guangzhou Bio-gene Technology Co. Ltd.
In a notable collaboration in May 2023, LaNova Medicines Ltd., a clinical-stage biotech firm based in China, partnered with AstraZeneca Plc. This alliance aims to advance LM-305, a preclinical GPRC5D-targeting antibody-drug conjugate (ADC) designed for treating relapsed or refractory multiple myeloma. AstraZeneca holds global rights for the research, development, and commercialization of this promising therapy.
View the full g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report:
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptor-family-c-group-5-member-d-gprc5d-targeted-therapies-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR
Emerging Trends Highlighting Innovation in GPRC5D Targeted Therapies
Leading companies in the sector are focusing intensely on developing bispecific T-cell engagers (BiTEs) to improve immune system targeting of cancer cells and enhance treatment outcomes. BiTEs function by simultaneously binding T-cells and cancer cells, effectively directing the immune response against tumors.
A recent example of this progress includes Johnson & Johnson's achievement in August 2023, when the European Commission approved TALVEY (talquetamab), a bispecific antibody therapy targeting GPRC5D. Designed for patients with relapsed or refractory multiple myeloma who have undergone at least three prior treatments, TALVEY has demonstrated an overall response rate exceeding 70% in clinical trials. Its benefits include subcutaneous administration, sustained improvements in patients' quality of life, and effectiveness even after prior bispecific or CAR-T therapies, addressing a significant unmet need in late-stage disease management.
Breakdown of Market Segments Defining the GPRC5D Targeted Therapies Industry
This market is segmented into several categories to capture the broad range of therapeutic approaches and applications:
1) Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
2) Indication: Multiple Myeloma; Solid Tumors; Other Indications
3) Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
4) Route of Administration: Intravenous; Subcutaneous; Other Routes
5) End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Further subdivisions include:
- Monoclonal Antibodies categorized into Fully Human, Humanized, Chimeric, and Murine types
- Bispecific Antibodies classified as Dual Targeting, Cross Linking, Immune Cell Engaging, and Cytotoxic variants
- CAR-T Cell Therapies divided into Autologous, Allogeneic, Next Generation, and Gene-Edited forms
- Other Therapy Types including Targeted Small Molecule Drugs, Receptor-Specific Inhibitors, Injectable Biologics, and Oral Targeted Therapeutics
This detailed segmentation allows stakeholders and researchers to better understand the diverse offerings and applications within the GPRC5D targeted therapies market, aiding informed decision-making and strategic planning.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Sub-Segments Transforming the G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Landscape here
News-ID: 4402431 • Views: …
More Releases from The Business Research Company
Leading Companies Advancing Innovation and Growth in the Implantable Neural Prob …
The implantable neural probes market is on a remarkable growth path, driven by advancements in neurotechnology and increasing investments in brain-machine interfacing. This sector is gaining significant attention due to its potential to revolutionize treatments for neurological disorders and enhance human-machine communication. Let's explore the market size, key players, emerging trends, and segmentation details shaping this dynamic industry.
Projected Growth and Market Size of the Implantable Neural Probes Market
The…
Human Acellular Dermis Market Overview: Major Segments, Strategic Developments, …
The human acellular dermis market is on track for significant advancement in the coming years, driven by innovations and increased applications in medical treatments. This evolving field offers promising prospects as it plays an essential role in regenerative medicine and reconstructive procedures. Here's an in-depth look at the market's expected growth, key players, emerging trends, and detailed segmentation.
Strong Market Projection for Human Acellular Dermis by 2030
The human acellular…
Segment Analysis and Major Growth Areas in the High-Density Polyethylene (HDPE) …
The high-density polyethylene (HDPE) conduit for utilities market is gaining significant attention as utility infrastructure evolves and modernizes. With increasing demands for smart, efficient, and resilient utility networks, this market is positioned for substantial growth over the coming years. Let's explore the market size projections, key players, main trends, and segmentation that define this expanding industry.
Anticipated Market Growth in the HDPE Conduit for Utilities Sector
The HDPE conduit for…
Key Strategic Developments and Emerging Changes Shaping the Heat Pump Booster fo …
The heat pump booster for domestic hot water (DHW) market is poised for significant expansion as demand for efficient and sustainable heating solutions continues to rise globally. With evolving technologies and growing environmental awareness, this sector is attracting considerable attention from industry leaders and consumers alike. Let's explore the current market size, the main factors propelling growth, key players, emerging trends, and the market's segmentation.
Strong Growth Outlook for the Heat…
More Releases for GPRC5D
Leads Biolabs' GPRC5D/CD3 Bispecific T-Cell Engager LBL-034 Earns FDA Fast Track …
Nanjing, China - January 28, 2026 - Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its key investigational asset LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary CD3 T-cell engager platform--LeadsBody platform, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory…
G-Protein-Coupled Receptor (GPCR) targeting drives key pharma innovations, with …
G-Protein-Coupled-Receptor-Targeting Market Size and Forecast
DataM Intelligence has published a new research report on "G-Protein-Coupled-Receptor-Targeting Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample PDF…
Car T Cell Therapy For Multiple Myeloma Pipeline 2025: FDA Approvals and Clinica …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical…
Car T Cell Therapy For Multiple Myeloma Pipeline 2025: MOA, ROA, FDA-Approved Dr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present…
Relapsed/Refractory Multiple Myeloma (RRMM) Market to Set Phenomenal Growth From …
Introduction
Multiple myeloma (MM) is the second most common hematological malignancy, characterized by abnormal proliferation of plasma cells in the bone marrow. Despite advances in treatment, the majority of patients eventually relapse or become refractory to therapy, creating a large and growing relapsed/refractory multiple myeloma (RRMM) population. This group faces poor prognosis and limited treatment durability, making RRMM one of the most urgent areas of innovation in oncology.
Traditional therapies such as…
Car T Cell Therapy For Multiple Myeloma Pipeline 2025: Therapies, MOA Insights, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present…
